Category: Posters

 |  Posters
Tags: , , , ,

Analysis of in vitro- to-in vivo predictions of transporter-mediated inhibition drug interactions for drugs approved by the USA Food and Drug Administration between 2013 and 2016

Presented at Asia Pacific ISSX conference, May 2018, Hangzhou City, China
Jingjing Yu and Isabelle Ragueneau-Majlessi

2018 Asia Pacific ISSX Poster Presentation – Transporter-mediated DDIs

Abstract

The present work aimed to systematically review transporter-based in vitro and clinical inhibition evaluations of drugs approved by the U.S. Food and Drug Administration (FDA) from 2013 to 2016. In vitro inhibition parameters, pharmacokinetics, and clinical drug-drug interaction (DDI) studies available in the New Drug Application (NDA) reviews were analyzed using the University of Washington Drug Interaction Database. Following recommendations from the 2012 FDA DDI guidance, in vitro to in vivo prediction estimates were calculated for the transporters the most often studied.

 |  Posters
Tags: , , , ,

Understanding the risk of clinically significant pharmacokinetic-based drug-drug interactions with drugs newly approved by the US FDA – a review of recent new drug applications (2013-2016)

Presented at ISSX conference, September 2017, Providence, RI, USA
Jingjing Yu and Isabelle Ragueneau-Majlessi

2017 ISSX Poster Presentation – 2013-2016 NDA Review

Abstract

The aim of the present work was to systematically review pharmacokinetic-based drug-drug interaction (DDI) data available in the most recent (2013-2016) New Drug Applications (NDAs) and highlight significant findings. The University of Washington Metabolism and Transport Drug Interaction Database was used to extract the results of metabolism, transport, and clinical DDI studies. All the DDI studies (new molecular entity (NME) as victim or perpetrator) with AUC changes ≥ 2-fold or < 2-fold but triggering dose recommendations were included in the analysis.

 |  Posters
Tags: , , ,

Identification and evaluation of clinical substrates of organic anion transporting polypeptides 1B1 and 1B3

Presented at ISSX conference, September 2017, Providence, RI, USA
Savannah J. McFeely, Yu, Tasha K. Ritchie, Jingjing Yu, Eva Gil Berglund, Anna Nordmark, and Isabelle Ragueneau-Majlessi

2017 ISSX Poster Presentation – Evaluation of Clinical Substrates of OATP1B1/3

Abstract

The aim of this work was twofold: i) Provide a thorough analysis of the available in vitro and in vivo data regarding OATP1B1/1B3 substrates, ii)Propose the most sensitive and selective probe markers of OATP1B1/1B3 activity.

 |  Posters
Tags: , , , ,

Detailed Evaluation of Pharmacokinetic-based Drug-drug Interaction Data Contained in New Drug and Biologic License Applications of Drugs Approved by the U.S. FDA in 2015

Presented at ASCPT conference, March 2017, Washington, DC, USA
Jingjing Yu, Zhu Zhou, Katie Owens, Tasha K. Ritchie, and Isabelle Ragueneau-Majlessi

2017 ASCPT Poster Presentation – 2015 NDA Review

Abstract

The aim of the present work was to perform a systematic analysis of metabolism, transport, and drug interaction data available in New Drug Applications (NDAs) and Biologic License Applications (BLAs) of drugs approved in 2015, and highlight significant findings.